IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy
AssigneeSeattle Children's Hospital
InventorsGiacomo Tampella, Michael C. Jensen, Adam Johnson
Life of this patent
Estimating the term…
Abstract
Some embodiments of the methods and compositions provided herein include cells having membrane-tethered. IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wild-type IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors, using these compositions. In some embodiments, the receptors include spacer regions, such as particular spacer regions designed to provide certain advantages.
Claims15
A nucleic acid encoding an IL-13 mutein-directed zetakine receptor, the zetakine receptor comprising:
- an extracellular domain comprising a mutein of IL-13;
- a spacer
- consisting of an IgG4 hinge-CH3 having 119 amino acids in length and having at least 90% sequence identity with the amino acid sequence set forth in SEQ ID NO:
- 10 or
- comprising an IgG4 hinge-CH2-CH3 comprising L235D and N297Q mutations;
- a transmembrane domain;
- and
- an intracellular signaling region,
- wherein the spacer links the mutein to the transmembrane domain, and
- wherein the transmembrane domain is linked to the intracellular signaling region.
Dependencies are inferred from the claim text.